Search

Hideho K Okada

from Mill Valley, CA
Age ~58
Get Report
Also known as:
Okada Hideho
Phone and address:
359 Durant Way, Mill Valley, CA 94941
(412) 512-2917
Related to:
Kazumi Okada, 64
Connected to:
Akinori Okada, 56Akira Okada, 64Brian M Okada, 51Charles N Okada, 78Clay K Okada, 59Clint J Okada, 64Gean J Okada, 67Hiroki Okada, 40Jim P Okada, 48Jordan A Okada, 38

Hideho Okada Phones & Addresses

  • 359 Durant Way, Mill Valley, CA 94941 (412) 512-2917
  • 3008 Beechwood Blvd, Pittsburgh, PA 15217 (412) 422-6186

Work

Company: Upmc Presbyterian Shadyside Address: 200 Lothrop Street, Pittsburgh, PA 15213

Education

School / High School: Nagoya University, Faculty Of Medicine 1991

Languages

English

Specialities

Neurosurgery

Professional Records

License Records

Hideho Okada

Address:
Pittsburgh, PA 15213
License #:
LT000333L - Expired
Category:
Medicine
Type:
Institutional License

Medicine Doctors

Hideho Okada Photo 1

Dr. Hideho Okada, Pittsburgh PA - MD (Doctor of Medicine)

View page
Specialties:
Neurosurgery
Address:
200 Lothrop St, Pittsburgh, PA 15213
(412) 647-3685 (Phone), (412) 647-0989 (Fax)
Languages:
English
Hospitals:
200 Lothrop St, Pittsburgh, PA 15213

Upmc Presbyterian Shadyside
200 Lothrop Street, Pittsburgh, PA 15213
Education:
Medical School
Nagoya University, Faculty Of Medicine
Graduated: 1991
Hideho Okada Photo 2

Hideho Okada

View page
Specialties:
Neurological Surgery
Hematology
Hematology & Oncology
Medical Oncology
Hideho Okada Photo 3

Hideho Okada, Pittsburgh PA

View page
Specialties:
Neurosurgeon
Address:
200 Lothrop St, Pittsburgh, PA 15213

Business Records

Name / Title
Company / Classification
Phones & Addresses
Hideho Okada
Hideho Okada MD
Neurosurgeon
5150 Ctr Ave, Pittsburgh, PA 15232
(412) 692-4742
Hideho Okada
Medical Doctor
Medical Oncology Associates PC
Hematologists & Oncologists
5115 Ctr Ave, Pittsburgh, PA 15232

Publications

Us Patents

Peptide Analogs Capable Of Enhancing Stimulation Of A Glioma-Specific Ctl Response

View page
US Patent:
7612162, Nov 3, 2009
Filed:
Sep 21, 2005
Appl. No.:
11/231618
Inventors:
Hideho Okada - Pittsburgh PA, US
Walter J. Storkus - Glenshaw PA, US
Junichi Eguchi - Pittsburgh PA, US
Hidemitsu Sato - Ohfuna, JP
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 38/00
A61K 38/08
A61K 38/10
US Classification:
530300, 530327, 530328, 514 2, 514 14, 514 15
Abstract:
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.

Th1-Associated Micrornas And Their Use For Tumor Immunotherapy

View page
US Patent:
8486911, Jul 16, 2013
Filed:
Aug 7, 2012
Appl. No.:
13/568457
Inventors:
Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A01N 43/04
A61K 31/70
US Classification:
514 44A, 514 44 R
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject.

Gene Therapy For The Treatment Of Solid Tumors Using Recombinant Adeno-Associated Virus Vectors

View page
US Patent:
20030223971, Dec 4, 2003
Filed:
Jan 13, 2003
Appl. No.:
10/342088
Inventors:
Gary Kurtzman - Menlo Park CA, US
Peter Colosi - Alameda CA, US
Jun Yoshida - Nagoya, JP
Masaaki Mizuno - Nagoya, JP
Hideho Okada - Pittsburgh PA, US
International Classification:
A61K048/00
C12N007/00
C12N015/861
US Classification:
424/093210, 514/044000, 435/235100, 435/456000
Abstract:
The use of recombinant adeno-associated virus (AAV) virions for the treatment of solid tumors is disclosed. The invention provides for the use of recombinant AAV virions to deliver an AAV vector containing a drug-susceptibility gene and a second gene capable of providing an ancillary effect to solid tumor cells. The second gene can be used to enhance the immunogenicity of the transduced tumor cell. Alternatively, the second gene can be used to provide a tumorstatic effect. The invention also provides for the use of recombinant AAV virions to deliver an interferon gene, or a tumor suppressor gene to provide a therapeutic effect in a transduced tumor cell.

Engineered Dendritic Cells And Uses For The Treatment Of Cancer

View page
US Patent:
20090123441, May 14, 2009
Filed:
Oct 8, 2008
Appl. No.:
12/247738
Inventors:
J. MARK BRAUGHLER - PITTSBURGH PA, US
PRASANNA KUMAR - COLLEGEVILLE PA, US
WALTER J. STORKUS - GLENSHAW PA, US
HIDEHO OKADA - PITTSBURGH PA, US
International Classification:
A61K 35/12
C12N 15/00
C12N 15/82
C12N 5/08
US Classification:
424 9321, 4353201, 435455, 435366
Abstract:
This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

Peptide Analogs Capable Of Enhancing Stimulation Of A Glioma-Specific Ctl Response

View page
US Patent:
20100008940, Jan 14, 2010
Filed:
Sep 17, 2009
Appl. No.:
12/561973
Inventors:
Hideho Okada - Pittsburgh PA, US
Walter J. Storkus - Glenshaw PA, US
Junichi Eguchi - Pittsburgh PA, US
Hidemitsu Sato - Ohfuna, JP
Assignee:
University of Pittsburgh - Of the Commonweath System of Higher Education - Pittsburgh PA
International Classification:
A61K 39/00
C07K 7/06
A61K 38/08
A61K 38/10
A61P 37/04
US Classification:
4241851, 530328, 514 15, 514 14
Abstract:
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.

Th1-Associated Micrornas And Their Use For Tumor Immunotherapy

View page
US Patent:
20100322909, Dec 23, 2010
Filed:
Jun 17, 2010
Appl. No.:
12/818016
Inventors:
Hideho Okada - Pittsburgh PA, US
Gary Kohanbash - Pittsburgh PA, US
Kotaro Sasaki - Pittsburgh PA, US
International Classification:
A61K 35/12
C12N 5/0783
A61P 35/00
US Classification:
424 9321, 435325
Abstract:
Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. In some embodiments, the T cell is a tumor antigen (TA)-specific T cell, such as a TA-specific CTL. Further provided is a method of treating cancer in a subject by selecting a subject with cancer and administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. In some embodiments of the method, the heterologous nucleic acid molecule encodes the miR-17-92 transcript or a portion thereof. In some embodiments, the isolated T cell is a TA-specific T cell, such as a CTL.

Interleukin-13 Receptor Alpha 2 Peptide-Based Brain Cancer Vaccines

View page
US Patent:
20120052080, Mar 1, 2012
Filed:
Aug 23, 2011
Appl. No.:
13/215938
Inventors:
Hideho Okada - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 38/17
A61P 35/00
A61K 39/00
US Classification:
4241841, 514 193
Abstract:
Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.

Engineered Dendritic Cells And Uses For The Treatment Of Cancer

View page
US Patent:
20120114620, May 10, 2012
Filed:
Sep 1, 2011
Appl. No.:
13/224091
Inventors:
J. Mark BRAUGHLER - Pittsburgh PA, US
Prasanna Kumar - Collegeville PA, US
Walter J. Storkus - Glenshaw PA, US
Hideho Okada - Pittsburgh PA, US
Assignee:
Intrexon Corporation - Blacksburg VA
International Classification:
A61K 35/14
A61P 35/00
G01N 33/566
C12N 15/85
C12N 5/10
US Classification:
424 9321, 4353201, 435325, 435 792
Abstract:
This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
Control profile
Hideho K Okada from Mill Valley, CA, age ~58 Get Report